相似文献
1
Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.
Medchemcomm. 2015 Apr 1;6(4):613-618. doi: 10.1039/C4MD00401A.
2
Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
Bioorg Med Chem Lett. 2022 Aug 15;70:128797. doi: 10.1016/j.bmcl.2022.128797. Epub 2022 May 14.
3
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
J Med Chem. 2013 May 9;56(9):3492-506. doi: 10.1021/jm301769u. Epub 2013 Apr 18.
4
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Eur J Med Chem. 2018 Jan 1;143:1406-1418. doi: 10.1016/j.ejmech.2017.10.040. Epub 2017 Oct 16.
5
Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Med Chem. 2018;14(8):831-850. doi: 10.2174/1573406414666180528111749.
6
Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group.
Front Chem. 2020 Apr 15;8:256. doi: 10.3389/fchem.2020.00256. eCollection 2020.
7
Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Bioorg Chem. 2019 Oct;91:103127. doi: 10.1016/j.bioorg.2019.103127. Epub 2019 Jul 18.
8
Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
Molecules. 2022 May 22;27(10):3335. doi: 10.3390/molecules27103335.
9
Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
ChemMedChem. 2015 Jun;10(6):971-6. doi: 10.1002/cmdc.201500019. Epub 2015 Apr 16.
10
Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6.
ACS Omega. 2017 Apr 30;2(4):1550-1562. doi: 10.1021/acsomega.6b00481. Epub 2017 Apr 20.
引用本文的文献
1
In Silico Insights into the Inhibition of ADAMTS-5 by Punicalagin and Ellagic Acid for the Treatment of Osteoarthritis.
Int J Mol Sci. 2025 Apr 25;26(9):4093. doi: 10.3390/ijms26094093.
2
Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on -Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer.
Pharmaceuticals (Basel). 2025 Feb 28;18(3):351. doi: 10.3390/ph18030351.
3
Discovery of Novel Metalloenzyme Inhibitors Based on Property Characterization: Strategy and Application for HDAC1 Inhibitors.
Molecules. 2024 Feb 29;29(5):1096. doi: 10.3390/molecules29051096.
4
Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline-Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors.
Pharmaceuticals (Basel). 2022 Apr 19;15(5):494. doi: 10.3390/ph15050494.
5
Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
Eur J Med Chem. 2022 Apr 15;234:114272. doi: 10.1016/j.ejmech.2022.114272. Epub 2022 Mar 11.
6
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases.
Molecules. 2021 Aug 25;26(17):5151. doi: 10.3390/molecules26175151.
7
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Chin Med J (Engl). 2020 Mar 20;133(6):699-715. doi: 10.1097/CM9.0000000000000685.
8
N -acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors.
R Soc Open Sci. 2019 Jun 5;6(6):190338. doi: 10.1098/rsos.190338. eCollection 2019 Jun.
9
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity.
Front Genet. 2019 Mar 1;10:133. doi: 10.3389/fgene.2019.00133. eCollection 2019.
10
Zinc binding groups for histone deacetylase inhibitors.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):714-721. doi: 10.1080/14756366.2017.1417274.
本文引用的文献
1
Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases.
Nanomedicine. 2014 May;10(4):721-32. doi: 10.1016/j.nano.2013.09.008. Epub 2013 Oct 5.
2
Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
J Biol Chem. 2013 Sep 13;288(37):26926-43. doi: 10.1074/jbc.M113.490706. Epub 2013 Jul 29.
3
The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts.
Biochem Soc Trans. 2013 Jun;41(3):741-9. doi: 10.1042/BST20130010.
4
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.
J Biol Chem. 2011 Jun 24;286(25):22211-8. doi: 10.1074/jbc.M110.180224. Epub 2011 Apr 29.
5
Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors.
Anal Biochem. 2011 Jan 15;408(2):309-15. doi: 10.1016/j.ab.2010.08.040. Epub 2010 Sep 22.
6
A direct synthesis of oxazoles from aldehydes.
Org Lett. 2010 Aug 20;12(16):3614-7. doi: 10.1021/ol101346w.
7
p21 in cancer: intricate networks and multiple activities.
Nat Rev Cancer. 2009 Jun;9(6):400-14. doi: 10.1038/nrc2657.
8
Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
J Med Chem. 2008 Apr 24;51(8):2447-56. doi: 10.1021/jm701384x. Epub 2008 Mar 19.
9
Anticancer activities of histone deacetylase inhibitors.
Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133.
10
Non-hydroxamate histone deacetylase inhibitors.
Curr Med Chem. 2005;12(24):2867-80. doi: 10.2174/092986705774454706.
Zotero 插件